Ann Arbor, MI, United States of America

Delphine Rolland

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.8

ph-index = 1


Company Filing History:


Years Active: 2016-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Delphine Rolland: Innovator in Cancer Research

Introduction

Delphine Rolland is a prominent inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of cancer research, particularly in the area of gene fusions and their implications for diagnosis and therapy.

Latest Patents

Delphine Rolland holds 2 patents. Her latest patents include "Recurrent gene fusions in cutaneous CD30-positive lymphoproliferative disorders," which provides kits, compositions, and methods for cancer diagnosis, research, and therapy. This invention focuses on recurrent gene fusions, such as those involving TYK2, as diagnostic markers and clinical targets for conditions like lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Another significant patent is related to "Compositions and methods relating to fusion protein biomarkers." This invention offers fusion proteins as biomarkers specific for chromosomal translocation-based conditions, including cancer, and outlines methods for detecting and quantifying these biomarkers.

Career Highlights

Delphine Rolland is affiliated with the University of Michigan, where she continues her research and innovation in cancer diagnostics and therapeutics. Her work has garnered attention for its potential impact on clinical practices and patient outcomes.

Collaborations

Delphine collaborates with notable colleagues, including Kojo Elenitoba-Johnson and Megan Lim, enhancing the research environment and fostering innovation in their shared field.

Conclusion

Delphine Rolland's contributions to cancer research through her patents and collaborations highlight her role as a key innovator in the field. Her work continues to pave the way for advancements in cancer diagnosis and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…